et al.84, screened a library of 3 million compounds in silico based on
one of the reported crystal structures82, and identified several
compounds (17–19) as effective inhibitors against PA–PB1 binding
in an ELISA-based assay and in cells (Fig. 5). Particularly, compound
17 was demonstrated to be active against an oseltamivir-resistant
strain84. These compounds were identified as lead compounds for
further antivirus drug development85. Studies with compound 19 and
its analogs have shown that cycloheptathiophene-3-carboxamide scaffold
is promising for new anti-influenza virus drug development85.